Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace and Franklin Templeton, and continued support from existing investorsLycia will use proceeds from financing to progress its lead programs into the clinic for autoimmune and inflammatory diseases SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the completion of an oversubscribed $106.6 million Series C financing.

Venrock Healthcare Capital Partners在新投资者Janus Henderson investors，Marshall Wace和Franklin Templeton的参与下领导了这一轮投资，现有投资者的持续支持Lycia将利用融资收益将其领先项目推进到加利福尼亚州旧金山南部的自身免疫和炎症性疾病诊所，2024年5月13日（环球通讯社）——细胞外蛋白降解领域的领导者Lycia Therapeutics，Inc.今天宣布完成超额认购的1.066亿美元C系列融资。

Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace and Franklin Templeton, and existing investors Redmile Group, RTW Investments, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), Invus, Eli Lilly and Company and Alexandria Venture Investments.

Venrock Healthcare Capital Partners领导了这一轮投资，新投资者Janus Henderson investors、Marshall Wace和Franklin Templeton以及现有投资者Redmile Group、RTW Investments、Blue Owl Healthcare Opportunities（前身为Cowen Healthcare Investments）、Invus、Eli Lilly and Company和Alexandria Venture Investments参与了此次投资。

Lycia’s next-generation degradation approach leveraging lysosomal targeting chimeras, or LYTACs, is designed to target the untapped extracellular proteome, including transmembrane and secreted proteins. Lycia has made notable progress advancing its pipeline of LYTACs and will use the proceeds from the Series C financing to advance its lead programs into the clinic for autoimmune and inflammatory diseases.

Lycia利用溶酶体靶向嵌合体或LYTACs的下一代降解方法旨在靶向未开发的细胞外蛋白质组，包括跨膜和分泌蛋白。Lycia在推进LYTACs渠道方面取得了显着进展，并将利用C系列融资的收益将其领先项目推进自身免疫性和炎性疾病的临床。

“We’re thrilled to welcome Venrock and our other new investors as we progress toward becoming a clinical stage company,” said Aetna Wun Trombley, Ph.D., President and Chief Executive Officer. “We’ve built and continue to enhance the LYTAC platform to access a wide range of extracellular proteins, including high expressing and high turnover targets.

安泰保险总裁兼首席执行官Wun Trombley博士表示：“我们很高兴欢迎Venrock和其他新投资者，因为我们正朝着成为临床阶段的公司迈进。”。“我们已经建立并继续增强LYTAC平台，以获得广泛的细胞外蛋白，包括高表达和高周转率目标。

This unique flexibility has already yielded a deep, diverse pipeline of LYTAC degraders aimed at depleting difficult-to-drug targets, includin.

这种独特的灵活性已经产生了一系列深度多样的LYTAC降解剂，旨在消耗难以药物靶点，包括。